CoChat

Bile Acid Changes After High-Dose Ursodeoxycholic Acid Treatment in Primary Sclerosing Cholangitis: Relation to Disease Progression

Open access
Sinakos, Emmanouil, Marschall, Hanns-Ulrich, Kowdley, Kris V., Befeler, Alex, Keach, Jill, Lindor, Keith · 2010 · Hepatology
Cited by 119

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

High-dose (28-30 mg/kg/day) ursodeoxycholic acid (UDCA) treatment improves serum liver tests in patients with primary sclerosing cholangitis (PSC) but does not improve survival and is associated with increased rates of serious adverse events. The mechanism for the latter undesired effect remains unclear. High-dose UDCA could result in the production of hepatotoxic bile acids, such as lithocholic acid (LCA), because of limited small bowel absorption of UDCA and conversion of UDCA by bacteria in the colon. We determined the serum bile acid composition in 56 patients with PSC previously enrolled in a randomized, double-blind controlled trial of high-dose UDCA versus placebo. Samples for analysis were obtained at the baseline and at the end of treatment. The mean changes in the UDCA level (16.86 versus 0.05 μmol/L) and total bile acid level (17.21 versus −0.55 μmol/L) were significantly higher in the UDCA group (n = 29) versus the placebo group (n = 27) when pretreatment levels were compared ( P < 0.0001). LCA was also markedly increased (0.22 versus 0.01 μmol/L) in the UDCA group compared to the placebo group ( P = 0.001). No significant changes were detected for cholic acid, deoxycholic acid, or chenodeoxycholic acid. Patients (n = 9) in the UDCA group who reached clinical endpoints of disease progression (the development of cirrhosis, varices, liver transplantation, or death) tended to have greater increases in their posttreatment total bile acid levels (34.99 versus 9.21 μmol/L, P < 0.08) in comparison with those who did not. Conclusion: High-dose UDCA treatment in PSC patients results in marked UDCA enrichment and significant expansion of the total serum bile acid pool, including LCA. Hepatology 2010

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.23631

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 119

Metadata

Authors
Sinakos, E., Marschall, H.-U., Kowdley, K. V., Befeler, A., Keach, J., & Lindor, K.
Venue
Hepatology
Published
2010-07
Volume
52
Issue
1
Pages
197-203
ISSN
0270-9139 (ISSN-L)
OpenAlex
W1982014243
Cited by
119
References
4
FWCI
6.21
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bile Acid Changes After High-Dose Ursodeoxycholic Acid Treatment in Primary Sclerosing Cholangitis: Relation to Disease Progression. https://app.cochat.ai/papers/10.1002/hep.23631
The paper
Sinakos, E., Marschall, H.-U., Kowdley, K. V., Befeler, A., Keach, J., & Lindor, K. (2010). Bile Acid Changes After High-Dose Ursodeoxycholic Acid Treatment in Primary Sclerosing Cholangitis: Relation to Disease Progression. Hepatology. https://doi.org/10.1002/hep.23631

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.